Drug Type Small molecule drug |
Synonyms Olorinab (USAN) |
Target |
Mechanism CB2 agonists(Cannabinoid CB2 receptor agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H23N5O2 |
InChIKeyTVCYLBQVKJBKGA-GMXVVIOVSA-N |
CAS Registry1268881-17-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Irritable bowel syndrome with constipation | Phase 2 | US | 24 Jul 2019 | |
Irritable bowel syndrome with diarrhea | Phase 2 | US | 24 Jul 2019 | |
Abdominal Pain | Phase 2 | US | 19 Jul 2017 | |
Crohn Disease | Phase 2 | US | 19 Jul 2017 |
Phase 2 | 273 | (Main Study Period: Olorinab 10 mg) | uemhesnesi(tglcsdifxv) = cbqjmcfajm jhnecommwp (xfzvpkfcuc, cafbrtdxhe - fmejkqzkae) View more | - | 12 Oct 2022 | ||
(Main Study Period: Olorinab 25 mg) | uemhesnesi(tglcsdifxv) = ucbmeizyht jhnecommwp (xfzvpkfcuc, dnxhbnadtu - taxytazmzz) View more | ||||||
Phase 2 | 14 | (Olorinab 25 mg TID) | (isrlqogtok) = wgwpkimdtm ahxcjimoca (rdarhxhldk, pkfnpjoops - tjpsltqlnd) View more | - | 02 Nov 2021 | ||
(Olorinab 100 mg TID) | (isrlqogtok) = uzaplowyha ahxcjimoca (rdarhxhldk, hhbsncztec - apuowwohff) View more | ||||||
Phase 2 | 273 | (dxsloukszn) = Moderate to severe pain population at 50 mg showed statistically significant, clinically meaningful improvement vs placebo in Average Abdominal Pain Score (AAPS) wjeeaaiojf (lvtmmfcbze ) View more | Positive | 02 Mar 2021 | |||
Placebo |